NOT KNOWN FACTS ABOUT COPYRIGHT 1 MG-SEMAGLUTIDE

The demo achieved both of those its primary endpoints, with semaglutide two.4 mg demonstrating statistically substantial and exceptional improvements in liver fibrosis without having worsening of steatohepatitis, as well as resolution of steatohepatitis without having worsening of liver fibrosis in people with MASH compared to placebo.oneInactive i